The UF Health Cancer Center will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held Jan. 19-21 in San Francisco, California, and virtually.
The symposium offers the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research and care.
Trials in Progress Poster Session
A phase II randomized therapeutic optimization trial for patients with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial.
Presenter: Sherise Rogers, M.D.
Authors include Ryan Thomas, M.D.; Brian Ramnaraign, M.D.; Jesus Fabregas, M.D.; Ilyas Sahin, M.D.; Stephen Staal, M.D.; Martina Murphy, M.D.; Anna Murillo, M.D.; Merry Jennifer Markham, M.D., FACP, Frederic Kaye, M.D.; Coy Heldermon, M.D., Ph.D.; Dennie Jones, M.D.; Julia Close, M.D.; Carmen Allegra, M.D.; Thomas George, M.D., FACP
Abstract #TPS280
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
Presenter: Sherise Rogers, M.D.
Authors include Brian Ramnaraign, M.D.; Ji-Hyun Lee, DrPH; Jesus Fabregas, M.D.; Ryan Thomas, M.D.; Carmen Allegra, M.D.; David DeRemer, Pharm.D., BCOP, FCCP, FHOPA; Thomas George, M.D., FACP; Jonathan Chatzkel, M.D.
Abstract #TPS625
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
Presenter: Sherise Rogers, M.D.
Authors include Ilyas Sahin, M.D.; Jesus Fabregas, M.D.; Ibrahim Nassour, M.D.; Brian Ramnaraign, M.D.; Kathryn Hitchcock, M.D., Ph.D.; Steven Hughes, M.D.; Ji-Hyun Lee, DrPH; Omar Kayaleh, M.D.; Z. Fan, Ph.D.; David DeRemer, Pharm.D.; Thomas George, M.D., FACP
Abstract #TPS778
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)
Authors include Thomas George, M.D., FACP
Abstract #TPS260
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Authors include Thomas George, M.D., FACP
Abstract #TPS258
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)
Authors include Thomas George, M.D., FACP
Abstract #TPS259
NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
Authors include Thomas George, M.D., FACP
Abstract #TPS284
Oral Abstract Session
Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)
Presenter: Thomas George, M.D., FACP
Abstract #7
Poster Session
Impact of COVID-19 pandemic on pancreatic cancer disparities and outcomes in Florida
Presenter: Alexander Lim, M.D.
Authors include XiangYang Lou, Ph.D.; Ibrahim Nassour, M.D.; Ramzi Salloum, Ph.D.; Sherise Rogers, M.D.
Abstract #667
Influence of clinical and tumor characteristics on survival in patients with hepatocellular carcinoma with bone metastasis
Authors include Jesus Fabregas, M.D.; Brian Ramnaraign, M.D.; Sherise Rogers, M.D.; Thomas George, M.D., FACP; Ilyas Sahin, M.D.
Abstract #525
Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers
Authors include Thomas George, M.D., FACP
Abstract #231
